The short answer
A single failed transfer is common and usually reflects the embryo or chance, not a problem with your body. Even a chromosomally tested embryo does not always implant 2. ESHRE's 2023 recommendations call failure 'recurrent' only once your predicted cumulative chance of implantation has passed 60%, and never after just one transfer 1.
Your transfer was done, you waited, and the beta hCG came back negative. That means no pregnancy was detected from this transfer. On its own, one negative result cannot tell you why.
This page separates two situations that often get lumped together. One failed transfer is an expected outcome in a large share of cycles. Recurrent implantation failure is something ESHRE defines by your odds, not by a fixed count of transfers 1. The page also sorts the tests and treatments offered after failed transfers by what ESHRE and the UK regulator, the HFEA, say about them 1,6.
How common is this?
31.5%
Chance of a positive pregnancy per transfer with embryos not chromosomally tested, women under 35 (European registry data used by ESHRE)1
25.9%
Same measure, women aged 35–391
15%
Same measure, women aged 40 and over1
62.5%
Live birth per single chromosomally normal (euploid) embryo transfer, women under 35, one US clinic network2
About half
People with RIF who had a live birth with ART within 5 years, in a study cited by ESHRE1
Reading your report
- Beta hCG
- The blood pregnancy test after transfer. A negative result means no pregnancy was detected from that transfer. ESHRE uses a positive test as its marker of successful implantation 1.
- Implantation
- The embryo attaching to and embedding in the lining of the womb (endometrium).
- Euploid / aneuploid
- Euploid means an embryo tested as having the expected number of chromosomes. Aneuploid means extra or missing chromosomes. You only know this if the embryo had PGT-A.
- PGT-A
- Preimplantation genetic testing for aneuploidy: a few cells are taken from a day 5–6 embryo and checked for chromosome number before transfer.
- Blastocyst
- An embryo grown in the lab to day 5 or 6, as opposed to a day 2–3 'cleavage-stage' embryo.
- Endometrial thickness (EMT)
- The thickness of the womb lining on scan before transfer, in millimetres.
- RIF
- Recurrent implantation failure: transfers of embryos thought to be viable have failed often enough, for your particular odds, to justify looking for a cause 1.
- ERA / endometrial receptivity test
- A biopsy of the womb lining analysed to predict the best day for transfer. Its value is disputed (see below).
Likely causes, most common first
| Cause | How you'd know | Test that tells you |
|---|---|---|
| The embryo had a chromosomal error | You usually can't. A well-graded embryo can still be aneuploid; only PGT-A shows chromosome number. | PGT-A in a future cycle (ESHRE: can be considered in RIF) 1 |
| Chance, even with a normal embryo | In one large US series, about 82 in 100 euploid single transfers in women under 35 gave a positive test, meaning the rest did not 2. | None needed after one transfer |
| A problem inside the uterine cavity (polyp, fibroid, adhesions, septum) | Seen on transvaginal or 3D ultrasound, or at hysteroscopy | 3D ultrasound or hysteroscopy (ESHRE: can be considered) 1 |
| Thin endometrium | Lining under 7 mm was linked to lower live birth in fresh cycles in a meta-analysis cited by ESHRE 1 | Re-measuring thickness (ESHRE: recommended) 1 |
| Fluid-filled blocked tube (hydrosalpinx) | Suspected on ultrasound | HSG or other tubal imaging if there is doubt (ESHRE: can be considered) 1 |
| Chronic endometritis (low-grade inflammation of the lining) | Biopsy with plasma-cell staining or hysteroscopy; there is no agreed threshold for diagnosis 1 | Endometritis testing (ESHRE: can be considered) 1 |
| Antiphospholipid syndrome | Past blood clots or recurrent miscarriage; confirmed by blood tests. Found in 2.88% of 185 RIF patients in one study 1 | Antiphospholipid antibody testing (ESHRE: recommended if you have extra clotting risk factors) 1 |
| A balanced chromosomal change in either partner | Karyotype blood test. Such changes were found in about 2.1% of RIF couples in the studies ESHRE reviewed 1 | Karyotyping of both partners (ESHRE: can be considered) 1 |
What did not cause this
"Stress or anxiety stopped the embryo implanting"
A BMJ meta-analysis of 14 studies (3,583 women) found emotional distress before treatment was not associated with whether a cycle led to pregnancy 10.
"I should have rested more after the transfer"
A meta-analysis of six randomised trials found bed rest after transfer was associated with fewer clinical pregnancies, not more 11.
"My body rejected the embryo"
ESHRE found no validated test of immune 'rejection': it does not recommend peripheral or uterine NK cell tests, T-cell tests or cytokine tests for RIF 1.
"The embryo was graded well, so it must be my uterus"
ESHRE notes that aneuploid embryos have negligible implantation potential and that embryo grading has limited reproducibility between centres 1. Grading cannot show chromosome errors.
Is one failed transfer the same as implantation failure?
No. Every embryo carries a chance of implanting, and with untested embryos that chance per transfer is well under half: 31.5% under 35, 25.9% at 35–39 and 15% at 40 and over in the European registry data ESHRE used 1. A negative result after one transfer is the more likely single outcome, not a sign that something is wrong.
ESHRE's 2023 good practice recommendations say at least two failed transfers are needed before implantation failure can be called recurrent 1. With untested embryos, most people need more than two before they reach ESHRE's threshold.
What are the odds of one embryo transfer working, by age?
For embryos that were not chromosomally tested, ESHRE's worked example uses pregnancy rates per transfer of 31.5% under 35, 25.9% at 35–39 and 15% at 40 and over 1.
For single euploid (PGT-A normal) embryos, a US study of 8,175 frozen transfers found a positive pregnancy test in 82.0% of transfers under 35, falling to 73.3% above 42 2. Live birth per transfer was 62.5% under 35, 58.3% at 35–37, 56.0% at 38–40, 52.2% at 41–42 and 52.9% above 42 2. Testing removes much of the age effect, but not all of it 2.
Age matters for untested embryos mainly because chromosomal errors rise. In 15,169 embryo biopsies, the proportion of patients with no euploid embryo among those biopsied was 2–6% at ages 26–37, 33% at 42 and 53% at 44 3.
These figures come from European registry data and US clinics. ESHRE says a centre's own data can be used to estimate a patient's odds 1, so ask your clinic for its per-transfer pregnancy rate for your age and embryo type. Any estimate should account for your age, whether embryos were tested, and the number and stage of embryos transferred 1. Under India's ART (Regulation) Act 2021, no more than three embryos may be placed in the uterus in one treatment cycle 13.
When does ESHRE call it recurrent implantation failure?
ESHRE describes RIF as the scenario in which transfers of embryos considered viable have failed to give a positive pregnancy test often enough, in a specific patient, to warrant considering further investigation or treatment 1.
The trigger is a 60% cumulative predicted chance of implantation 1. You add up the chance from each transfer so far; if that running total has passed 60% without a positive test, ESHRE says you should be counselled on investigations and treatment options 1. Below that, it advises simply proceeding with another transfer 1.
In ESHRE's worked example, a 36-year-old with an estimated 27.6% chance of pregnancy per attempt has a 47% cumulative chance after two transfers and 62% after three, so investigation is suggested only if the third transfer fails 1. Its rough guide based on published pregnancy rates:
Which tests and treatments does ESHRE recommend for RIF?
ESHRE made 19 recommendations on investigations and 13 on treatments, sorted into three groups: recommended, can be considered, and not recommended 1. 'Not recommended' means not offered routinely; ESHRE says this is not a ban in every circumstance, because the evidence rarely supports so absolute a statement 1.
- Recommended: reviewing lifestyle factors in both partners; re-measuring endometrial thickness and reviewing oestrogen treatment if the lining stays thin; antiphospholipid antibody testing if you have extra risk factors for clotting 1.
- Recommended if a result is abnormal: genetic counselling, and PGT where relevant, if either partner has a chromosomal abnormality 1.
- Can be considered: karyotyping both partners, 3D ultrasound or hysteroscopy, testing specific aspects of endometrial function, chronic endometritis testing (with antibiotics if found), thyroid function, progesterone levels, PGT-A, and blastocyst-stage transfer 1.
- Not recommended (tests): vitamin D, uterine or vaginal microbiome profiling, peripheral or uterine NK cells, uterine T lymphocytes, blood cytokines, HLA-C compatibility, embryo mitochondrial DNA, and sperm DNA fragmentation or sperm FISH 1.
- Not recommended (treatments): vitamin D treatment, endometrial scratching, G-CSF, intralipid infusion, IVIG, intrauterine PBMC, PRP or hCG, low molecular weight heparin to improve pregnancy chances, GnRH agonist or letrozole pre-treatment, and assisted hatching 1.
- Named by ESHRE as research priorities before routine use: vitamin D, immune factors and targeted immune treatments, receptivity tests, endometritis testing, microbiome profiling, treatments for thin lining, sperm DNA fragmentation, PBMC, PRP, intrauterine hCG and antioxidants 1.
Is an ERA test worth it after a failed transfer?
The largest trial says no benefit for the general IVF population. In a double-blind JAMA trial of 767 patients with euploid embryos, live birth was 58.5% with receptivity-timed transfer and 61.9% with standard timing 4. That trial excluded people with recurrent implantation failure 4, so it does not directly answer the RIF question.
An earlier multicentre trial found comparable outcomes per transfer by intention-to-treat; higher cumulative live birth appeared only among those who completed the protocol 1. ESHRE's RIF document concludes there are insufficient data to recommend any commercially available receptivity test, though testing specific aspects of endometrial function can be considered 1. ESHRE's add-ons recommendations do not recommend the currently available tests 5, and the HFEA rates receptivity testing red, meaning moderate/high-quality evidence suggests it may reduce treatment effectiveness 6.
What about NK cell tests, immune panels and immune treatments?
ESHRE does not recommend peripheral or uterine NK cell testing, noting that reference ranges vary substantially between studies and it is uncertain whether cell counts reflect function 1. It also does not recommend intralipid, IVIG or intrauterine PBMC for RIF 1. Reported side effects of IVIG include aseptic meningitis, kidney failure and blood clots 1.
The HFEA rates IVIG and steroids red for most fertility patients and intralipids grey (not enough good evidence to rate) 6. In the UK, the HFEA and professional and patient bodies agreed in October 2023 that treatments without strong evidence of safety or effectiveness should only be offered in a research setting, and patients should not be charged extra to take part in research 6.
Heparin is different when antiphospholipid syndrome has actually been diagnosed; that is treated under its own guidelines 1. Without that diagnosis, ESHRE does not recommend heparin to improve the chance of pregnancy in RIF 1.
What if no cause is found?
ESHRE is plain that much is still unknown about why implantation fails, and it asks clinicians to be honest about the lack of benefit of many tests and treatments offered for RIF 1. It also says patients can be reassured, based on their own estimated chances, that simply continuing treatment can be a good option; a study it cites found about half of people with RIF had a live birth with ART within five years 1.
ESHRE notes that some couples may benefit from moving to donor eggs or sperm, which could bypass an unidentified problem, but studies are still needed to confirm this 1.
It depends on…
How many transfers have not worked, and were the embryos tested?
One transfer, any embryo
Not recurrent by ESHRE's definition, which needs at least two 1. Review the basics, then usually proceed to the next transfer.
Two transfers of euploid (PGT-A normal) embryos
In ESHRE's worked example this passes the 60% threshold, so counselling on investigations is suggested 1.
Several transfers of untested embryos
Depends on age: ESHRE's rough guide suggests investigating after 3 under 35, 4 at 35–39 and 6 at 40 and over 1.
Has a specific cause been found?
Yes, such as thin lining, a polyp, endometritis, antiphospholipid antibodies or a parental chromosome change
Treat that finding; ESHRE lists a targeted step for each 1.
No
ESHRE advises limiting tests and treatments to those with a clear rationale; continuing treatment is a reasonable option 1.
What's worth checking
- List every transfer: date, number of embryos, day 3 or day 5, grade, tested or untested.
- Note your age at the egg collection each embryo came from, not your age now.
- Ask your clinic for its own per-transfer pregnancy rate for your age and embryo type.
- Check the endometrial thickness recorded before each transfer.
- Check whether your uterine cavity was assessed by 3D scan or hysteroscopy before treatment.
- Tell your doctor about any past blood clots or recurrent miscarriage.
- Ask whether a karyotype has been done for both partners.
- Before paying for any add-on, ask for its ESHRE category and HFEA rating.
What could change next cycle
15 options, by strength of evidence
- Good evidence it helps 1
- Mixed, or some groups only 6
- Not enough studies yet 6
- Evidence says it doesn't help 2
Ratings follow the evidence reviews cited beside each option, not our opinion.
- Another transfer without extra tests, if you are below ESHRE's 60% thresholdGood evidence it helps
ESHRE advises simply proceeding to another transfer below the threshold 1; cumulative live birth kept rising with further cycles in UK data 12.
- Reviewing oestrogen preparation if the lining stays thinMixed, or some groups only
ESHRE: recommended, but it only helps if your lining was actually thin 1.
- Genetic counselling and PGT if a parent carries a chromosomal changeMixed, or some groups only
ESHRE: recommended when found; applies to a small minority of couples (about 2.1%) 1.
- Hysteroscopy or 3D ultrasound of the uterusMixed, or some groups only
ESHRE: can be considered, especially if a scan suggests a problem; in RIF without known pathology, the TROPHY trial found 29% live birth with and without hysteroscopy 1.
- Antibiotics for confirmed chronic endometritisMixed, or some groups only
ESHRE: can be considered; systematic reviews conflict and diagnosis is not standardised 1.
- PGT-A (chromosome testing of embryos)Mixed, or some groups only
ESHRE RIF: can be considered, though trials in RIF showed no live-birth gain 1. HFEA: red for chance of a baby, green for reducing miscarriage, for most patients 7.
- Blastocyst (day 5) transfer instead of day 3Mixed, or some groups only
ESHRE: can be considered; low-quality evidence of higher live birth with fresh blastocyst transfer in general IVF 1.
- ERA-timed transferEvidence says it doesn't help
Largest trial: 58.5% vs 61.9% live birth, no benefit 4; HFEA rates it red 6.
- Endometrial scratchingNot enough studies yet
Cochrane 2026: effect on live birth unclear 9; ESHRE: not recommended in RIF 1; HFEA: grey for RIF 8.
- Immune treatments (intralipid, IVIG, steroids, G-CSF, PBMC)Not enough studies yet
ESHRE: not recommended in RIF 1. HFEA: IVIG and steroids red, intralipids grey 6.
- Heparin (LMWH) without diagnosed antiphospholipid syndromeNot enough studies yet
ESHRE: not recommended to improve pregnancy in RIF; trials were small, with 71 women for live birth 1.
- PRP or hCG placed into the uterusNot enough studies yet
ESHRE: not recommended pending better trials 1; HFEA rates PRP red 6.
- Assisted hatchingNot enough studies yet
- Time-lapse embryo imagingEvidence says it doesn't help
HFEA: black, meaning moderate/high-quality evidence shows no effect on the chance of a baby 6; ESHRE: not recommended to improve live birth 5.
- Donor eggs or spermNot enough studies yet
ESHRE: may bypass an unidentified problem, but studies are needed to confirm it improves chances after RIF 1.
Questions to ask your doctor
- Given my age, embryo stage and number transferred, what was my estimated chance per transfer, and have I passed ESHRE's 60% threshold 1?
- What are this clinic's own pregnancy rates per transfer for my age group and embryo type?
- Was my endometrial thickness adequate at each transfer, and has my uterine cavity been checked?
- For each test you suggest, which ESHRE category is it in, and what would we do differently depending on the result?
- If you suggest PGT-A, how many embryos do we have, and how could it change my chance of a baby versus my chance of miscarriage?
- Is any add-on you suggest part of a registered trial, and what will it cost?
Questions people ask
Does a negative beta hCG mean the embryo never implanted?
It means no pregnancy was detected from that transfer; ESHRE uses a positive pregnancy test as its marker of implantation 1. If a test was positive and then fell, that is a biochemical (chemical) pregnancy, which is a different situation with its own page.
Should I switch to a frozen transfer after a failed fresh transfer?
There is no RIF-specific evidence: ESHRE found no studies of changing transfer strategy, including frozen transfer, in RIF 1. In general IVF, ESHRE does not recommend routine freeze-all, citing a Cochrane review that found similar cumulative live birth with freeze-all and fresh transfer 5. Freezing can still be advised for specific reasons, such as OHSS risk or PGT 5.
Could my husband's sperm be why transfers keep failing?
Can a thyroid problem cause implantation failure?
What should I bring to a second-opinion appointment after failed transfers?
Bring your stimulation chart, the embryology report (eggs, fertilisation, embryo grades and day of freezing), transfer notes with endometrial thickness, any PGT-A reports, and all test results. A doctor can then estimate your cumulative chance so far, which is the number ESHRE's definition depends on 1.
Does a failed transfer mean there is something wrong with my uterus?
Usually not. Embryos fail even when their chromosomes have been checked: in 8,175 single euploid transfers, 18.0% of transfers in women under 35 gave no positive test 2. When failures do repeat, ESHRE's uterine steps are re-measuring endometrial thickness and reviewing oestrogen if the lining stays thin, with 3D ultrasound or hysteroscopy if a problem is suspected 1. It does not recommend immune or receptivity testing of the lining 1.
Should my progesterone level have been tested around the time of transfer?
It can be. ESHRE says assessment of late follicular and mid-luteal progesterone levels can be considered when implantation keeps failing, noting increasing evidence that low blood progesterone on the day of transfer is linked with poorer outcomes 1. It also warns that published cut-off values may not hold in another laboratory's assay, so it recommends each centre validate its own cut-offs locally 1.
Could a difficult embryo transfer be the reason it failed?
It is worth asking about. A systematic review of randomised trials of transfer technique linked ultrasound-guided transfer and soft catheters to higher clinical pregnancy rates 11. Your transfer note should record whether ultrasound was used, which catheter was used and whether it passed easily. One difficult transfer does not explain a failure by itself, but it is a concrete detail to review before the next one.
How many days after a transfer does an embryo implant?
The clearest measurements come from natural conception rather than IVF. Among 221 women giving daily urine samples, hCG first appeared 6 to 12 days after ovulation, and 84% of pregnancies that lasted at least six weeks implanted on day 8, 9 or 10; the risk of early loss rose the later implantation happened 15. After a transfer, the blood test is still the only way to know, and ESHRE treats a positive hCG as the marker of implantation 1.
Will losing weight or changing my diet make the next transfer work?
ESHRE recommends reviewing lifestyle in both partners when transfers keep failing, because habits can change during treatment 1. It is also blunt that well-designed studies showing better ART outcomes after lifestyle changes remain scarce, and that while BMI is treated as a risk factor for ART failure, most studies indicate obesity does not significantly affect embryo quality 1. None of this makes a failed transfer something you caused.
Should we put two embryos back next time instead of one?
It raises the chance per transfer and the chance of twins together. In a Cochrane review of 17 randomised trials (2,505 women), one double transfer gave a higher live birth rate than one single transfer, while repeated single transfers reached a similar cumulative rate: in its illustration a 13% multiple pregnancy risk after one double transfer fell to 0% to 3% 14. Indian law allows no more than three embryos in one treatment cycle 13.
If this embryo did not implant, will my other frozen embryos also fail?
One failure is not evidence about the rest. ESHRE's method gives each transfer its own chance and adds those chances into a running total, rather than treating a failure as information about the remaining embryos 1. That is why its trigger for investigation is a cumulative 60% chance, not a fixed number of failures 1. In UK data, cumulative live birth kept rising with further cycles 12.
Sources
- ESHRE Working Group on Recurrent Implantation Failure; Cimadomo D, de los Santos MJ, Griesinger G, et al. ESHRE good practice recommendations on recurrent implantation failure. Hum Reprod Open. 2023;2023(3):hoad023. ESHRE / Human Reproduction Open
- Reig A, Franasiak J, Scott RT Jr, Seli E. The impact of age beyond ploidy: outcome data from 8175 euploid single embryo transfers. J Assist Reprod Genet. 2020;37(3):595-602. Journal of Assisted Reproduction and Genetics
- Franasiak JM, Forman EJ, Hong KH, et al. The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertil Steril. 2014;101(3):656-663.e1. Fertility and Sterility
- Doyle N, Jahandideh S, Hill MJ, Widra EA, Levy M, Devine K. Effect of timing by endometrial receptivity testing vs standard timing of frozen embryo transfer on live birth in patients undergoing in vitro fertilization: a randomized clinical trial. JAMA. 2022;328(21):2117-2125. JAMA
- ESHRE Add-ons Working Group; Lundin K, Bentzen JG, Bozdag G, et al. Good practice recommendations on add-ons in reproductive medicine. Hum Reprod. 2023;38(11):2062-2104. ESHRE / Human Reproduction
- Human Fertilisation and Embryology Authority. Treatment add-ons with limited evidence (ratings list). HFEA (UK regulator)
- Human Fertilisation and Embryology Authority. Pre-implantation genetic testing for aneuploidy (PGT-A): treatment add-on ratings. HFEA (UK regulator)
- Human Fertilisation and Embryology Authority. Endometrial scratching: treatment add-on ratings. HFEA (UK regulator)
- Perera AK, Gan J, Afroz A, Armstrong S, Raine-Fenning N, Martins WP, Lensen SF. Endometrial injury in women undergoing in vitro fertilisation (IVF). Cochrane Database Syst Rev. 2026;5:CD009517. Cochrane
- Boivin J, Griffiths E, Venetis CA. Emotional distress in infertile women and failure of assisted reproductive technologies: meta-analysis of prospective psychosocial studies. BMJ. 2011;342:d223. BMJ
- Tyler B, Walford H, Tamblyn J, Keay SD, et al. Interventions to optimize embryo transfer in women undergoing assisted conception: a comprehensive systematic review and meta-analyses. Hum Reprod Update. 2022;28(4):480-500. Human Reproduction Update
- Smith ADAC, Tilling K, Nelson SM, Lawlor DA. Live-birth rate associated with repeat in vitro fertilization treatment cycles. JAMA. 2015;314(24):2654-2662. JAMA
- The Assisted Reproductive Technology (Regulation) Act, 2021 (Act No. 42 of 2021), Government of India. Section 24(b). Government of India (Gazette text via PRS Legislative Research)
- Kamath MS, Mascarenhas M, Kirubakaran R, Bhattacharya S. Number of embryos for transfer following in vitro fertilisation or intra-cytoplasmic sperm injection. Cochrane Database Syst Rev. 2020;8(8):CD003416. Cochrane
- Wilcox AJ, Baird DD, Weinberg CR. Time of implantation of the conceptus and loss of pregnancy. N Engl J Med. 1999;340(23):1796-1799. New England Journal of Medicine